Table 1.
Significantly enriched pathways in KLF7_high head and neck squamous cell carcinoma samples. ERBB, V‐erb‐b2 erythroblastic leukemia viral oncogene homolog; FDR, false discovery rate; Hits, gene counts in pathway; MAPK, mitogen‐activated protein kinase; NES, normalized enrichment score.
| Pathway | Hits | NES | FDR |
|---|---|---|---|
| Neurotrophin signaling pathway | 124 | 2.183 | 0.00107 |
| GnRH signaling pathway | 97 | 2.166 | 0.00147 |
| Long‐term potentiation | 67 | 2.092 | 0.00631 |
| ERBB signaling pathway | 86 | 2.052 | 0.0112 |
| Prostate cancer | 88 | 1.934 | 0.0121 |
| Adipocytokine signaling pathway | 62 | 1.941 | 0.0128 |
| SNARE interactions in vesicular transport | 38 | 1.934 | 0.0129 |
| Regulation of actin cytoskeleton | 201 | 1.944 | 0.0135 |
| GAP junction | 87 | 2.007 | 0.0140 |
| Long‐term depression | 65 | 1.977 | 0.0142 |
| Vasopressin‐regulated water reabsorption | 41 | 1.904 | 0.0142 |
| Insulin signaling pathway | 131 | 1.961 | 0.0142 |
| Renal cell carcinoma | 66 | 1.945 | 0.0146 |
| Focal adhesion | 196 | 1.905 | 0.0149 |
| Amino sugar and nucleotide sugar metabolism | 43 | 1.954 | 0.0153 |
| Oocyte meiosis | 106 | 2.021 | 0.0153 |
| Ubiquitin‐mediated proteolysis | 130 | 1.907 | 0.0155 |
| Chronic myeloid leukemia | 73 | 1.948 | 0.0156 |
| MAPK signaling pathway | 252 | 1.980 | 0.0157 |